tbuckley/cabot-search huggingface dataset:
The Prevalence and Outcomes of Transradial Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Authors: Dmitri V. Baklanov, Lisa A. Kaltenbach, Steven P. Marso, Sumeet S. Subherwal, Dmitriy N. Feldman, Kirk N. Garratt, Jeptha P. Curtis, John C. Messenger, Sunil V. Rao
Journal: Journal of the American College of Cardiology (2012)
Impact of erythropoietin (EPO) on irradiation effect on the EPO receptor–positive head and neck cancer
Authors: C. Lo Nigro, M. Maffi, J. Fischel, F. Tonissi, G. Numico, G. Milano, M. Merlano
Journal: Journal of Clinical Oncology (2007)

6058 Background: Anemia frequently occurs in Head and Neck Squamous Cell Carcinoma (HNSCC) and has been associated with decreased quality of life, impaired treatment outcomes and shortened survival. Furthermore, anemia is a causative factor of tumor hypoxia, which compromises the efficacy of radiotherapy (RT). In order to circumvent the negative effects of anemia, several attempts have been made including the use of EPO, particularly in HNSCC. However, recent clinical data suggest a detrimental effect of EPO on survival for HNSCC patients treated with RT plus EPO. Methods: The HNSCC CAL-166 cell line, which is wild type p53 and expresses the EPO receptor (EPOR), was investigated in the present study; a MTT test was used to examine the effects of EPO on the cellular response to RT. Extended preliminary experiments were performed to standardize the conditions (time of exposure to hypoxia and time to return of normal culture conditions) and the administration of radiation (fractionated or in single dose) to optimize the effects of hypoxia on radiation response. Cells were exposed to a X-rays source at escalating doses from 2–20 Gy and showed classical dose- response curves. Hypoxia was mimed using a ‘Bug-Box‘ anaerobic workstation for 24–48 hours. Results: After a single RT dose of 10 Gy, the data confirmed the negative effect of hypoxia, directly related to the duration of hypoxia (% surviving cells when irradiated in normoxia: 43.95 ± 4.24; when irradiated after 24 hours of hypoxia, 62.4 ± 8.3 or after 48 hours, % surviving cells 70.8 ± 7.4; p = 0.001 versus RT in normoxia). The addition of EPO, from 24 hours before RT to 72 hours after, until MTT test, did not modify the cytotoxic effect of RT in hypoxic, but also in oxic conditions. Conclusions: These preliminary data do not support a direct negative effect of EPO when treating EPOR positive tumor cells with irradiation. Additional data concern the molecular impact of EPO on tumor cell lines with examination of EPOR, HIF-1 alpha and EGFR. No significant financial relationships to disclose.
Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial
Authors: Dale M Needham, Elizabeth Colantuoni, Victor D Dinglas, Catherine L Hough, Amy W Wozniak, James C Jackson, Peter E Morris, Pedro A Mendez-Tellez, E Wesley Ely, Ramona O Hopkins
Journal: The Lancet Respiratory Medicine (2016)
Multicenter, prospective, randomized, phase-II trial of sequential and concurrent oral bexarotene in combination with chemotherapy, in previously untreated patients with advanced NSCLC
Authors: R. Bordoni, G. Volas-Redd, L. Zemsky, M. Saleh, C. Powell, S. Harris
Journal: Journal of Clinical Oncology (2004)

7353 Background: Recent Phase III trials have failed to show significant differences in survival for patients with Stage IIIB/IV NSCLC treated with various platinum-based chemotherapy regimens. New effective therapies are still needed. Bexarotene (Targretin), a synthetic retinoid analogue approved for patients with cutaneous T-cell lymphoma, binds preferentially to the rexinoid receptor (RXR), potentially providing therapeutic benefits in RXR-expressing tumors. Phase I-II studies of bexarotene in advanced NSCLC have shown promising activity. Methods: Chemotherapy-naïve patients with Stage IV and IIIB with pleural effusion, and ECOG performance status (PS) 0–2, were enrolled on study and treated with carboplatin IV AUC-6 Day 1 and paclitaxel IV 100 mg/m2 Days 1, 8 and 15, every 28 days for up to 4 cycles. Patients were randomized to receive bexarotene orally 400 mg/m2/day either concurrently with chemotherapy from Day 1 or sequentially at the completion of the chemotherapy. Patients were started an antilipid agent 7 days prior to bexarotene therapy. Results: 16 patients (median age 67 years) have been enrolled thus far, 9 of whom have completed the planned 4 cycles of chemotherapy (5 in the sequential and 4 in the concurrent arm). Three patients remain on active therapy and 13 patients are off trial; 6 due to progressive disease, 3 for deteriorating PS, 3 for bexarotene-associated adverse events (AE) and 1 withdrew. Overall, AE were reported in 48% of patients in the sequential arm vs. 51% in the concurrent arm. The incidence of Grade 3–4 AE, regardless of the treatment arm or phase, was < 5%. There were no cases of pancreatitis and no treatment-associated deaths. Conclusions: Our data indicate no detrimental effect of adding bexarotene to weekly carboplatin/paclitaxel. Updated data will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ligand Pharmaceuticals
Transposon Insertions, Structural Variations, and SNPs Contribute to the Evolution of the Melon Genome
Authors: Walter Sanseverino, Elizabeth Hénaff, Cristina Vives, Sara Pinosio, William Burgos-Paz, Michele Morgante, Sebastián E. Ramos-Onsins, Jordi Garcia-Mas, Josep Maria Casacuberta
Journal: Molecular Biology and Evolution (2015)

The availability of extensive databases of crop genome sequences should allow analysis of crop variability at an unprecedented scale, which should have an important impact in plant breeding. However, up to now the analysis of genetic variability at the whole-genome scale has been mainly restricted to single nucleotide polymorphisms (SNPs). This is a strong limitation as structural variation (SV) and transposon insertion polymorphisms are frequent in plant species and have had an important mutational role in crop domestication and breeding. Here, we present the first comprehensive analysis of melon genetic diversity, which includes a detailed analysis of SNPs, SV, and transposon insertion polymorphisms. The variability found among seven melon varieties representing the species diversity and including wild accessions and highly breed lines, is relatively high due in part to the marked divergence of some lineages. The diversity is distributed nonuniformly across the genome, being lower at the extremes of the chromosomes and higher in the pericentromeric regions, which is compatible with the effect of purifying selection and recombination forces over functional regions. Additionally, this variability is greatly reduced among elite varieties, probably due to selection during breeding. We have found some chromosomal regions showing a high differentiation of the elite varieties versus the rest, which could be considered as strongly selected candidate regions. Our data also suggest that transposons and SV may be at the origin of an important fraction of the variability in melon, which highlights the importance of analyzing all types of genetic variability to understand crop genome evolution.
Clinicopathological Features of Kras, Nras, Braf and Pik3Ca Mutations in Japanese Patients with Mcrc
Authors: Akihito Kawazoe, Kohei Shitara, Hideaki Bando, Yasutoshi Kuboki, Tomohiro Kadota, Wataru Okamoto, Takashi Kojima, Nozomu Fuse, Takayuki Yoshino
Journal: Annals of Oncology (2014)
Cyclophosphamide and the heart.
Authors: B H Kushner, N K Cheung
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.3.529 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1999724 Cyclophosphamide and the heart. B H KushnerxB H KushnerSearch for articles by this author , N K CheungxN K CheungSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.3.529 PDF "Cyclophosphamide and the heart.." Journal of Clinical Oncology, 9(3), pp. 529–530© 1991 by American Society of Clinical Oncology
Identification of biologic and inflammatory markers for predicting clinical responses to sipuleucel-T in CRPC.
Authors: Mehmet Faith Hepgur, Tanya B. Dorff, Lucy Brining, Jie Cai, Jacek K. Pinski, Mary Reed, Michael Luther, Betty Chan, David I. Quinn
Journal: Journal of Clinical Oncology (2014)

134 Background: Sip-T prolongs OS in asymptomatic or minimally symptomatic CRPC. We prospectively evaluated biomarkers in men receiving Sip-T to identify predictors of SDP and OS. Methods: Circulating tumor cells (CTC), PSA, prostatic acid phosphatase (PAP), albumin (Alb), hemoglobin (Hb), serum alkaline phosphatase (SAP), LDH, C-reactive protein (CRP) and β2-microglobulin (β2m) were evaluated in a reference lab. SipT product parameters, CD54, CD54 upregulation (UPREG) and total nucleated cells (TNC) were measured by Dendreon. Survival was evaluated using Kaplan-Meier estimates; univariate Cox regression was used to investigate the effect of biomarkers on SDP and OS using 2-sided tests and corrected for multiple comparisons. Results: 92 men who received Sip-T were included. Median age was 69 (48-90). The median follow-up was 14 (1.3 –34.7) mos, and 33% of men had died. 21 men developed SDP at a median of 5.7 (1-19) mos. Univariate analyses of biomarkers and product parameters are shown in the table. In multivariate analysis independent risks factors were LDH (p=.04) and β2m (p=.004) for SDP; LDH (p=.04), PSA (p=.012), age (p=.012) and UPREG (p=.006) for OS. Conclusions: CTC, CRP, LDH are associated with outcomes after Sip-T, similar to findings with hormone or cytotoxic therapy. Correlation of improved OS with low PSA and higher Hgb, albumin and Sip-T immune parameters supports the hypothesis that SipT is more effective with low disease burden. Prediction of early disease progression by β2m and LDH warrants further study. [Table: see text]
Intimate Partner Violence and Depression Symptom Severity among South African Women during Pregnancy and Postpartum: Population-Based Prospective Cohort Study
Authors: Alexander C. Tsai, Mark Tomlinson, W. Scott Comulada, Mary Jane Rotheram-Borus
Journal: PLoS Medicine (2016)

Background Violence against women by intimate partners remains unacceptably common worldwide. The evidence base for the assumed psychological impacts of intimate partner violence (IPV) is derived primarily from studies conducted in high-income countries. A recently published systematic review identified 13 studies linking IPV to incident depression, none of which were conducted in sub-Saharan Africa. To address this gap in the literature, we analyzed longitudinal data collected during the course of a 3-y cluster-randomized trial with the aim of estimating the association between IPV and depression symptom severity. Methods and Findings We conducted a secondary analysis of population-based, longitudinal data collected from 1,238 pregnant women during a 3-y cluster-randomized trial of a home visiting intervention in Cape Town, South Africa. Surveys were conducted at baseline, 6 mo, 18 mo, and 36 mo (85% retention). The primary explanatory variable of interest was exposure to four types of physical IPV in the past year. Depression symptom severity was measured using the Xhosa version of the ten-item Edinburgh Postnatal Depression Scale. In a pooled cross-sectional multivariable regression model adjusting for potentially confounding time-fixed and time-varying covariates, lagged IPV intensity had a statistically significant association with depression symptom severity (regression coefficient b = 1.04; 95% CI, 0.61–1.47), with estimates from a quantile regression model showing greater adverse impacts at the upper end of the conditional depression distribution. Fitting a fixed effects regression model accounting for all time-invariant confounding (e.g., history of childhood sexual abuse) yielded similar findings (b = 1.54; 95% CI, 1.13–1.96). The magnitudes of the coefficients indicated that a one–standard-deviation increase in IPV intensity was associated with a 12.3% relative increase in depression symptom severity over the same time period. The most important limitations of our study include exposure assessment that lacked measurement of sexual violence, which could have caused us to underestimate the severity of exposure; the extended latency period in the lagged analysis, which could have caused us to underestimate the strength of the association; and outcome assessment that was limited to the use of a screening instrument for depression symptom severity. Conclusions In this secondary analysis of data from a population-based, 3-y cluster-randomized controlled trial, IPV had a statistically significant association with depression symptom severity. The estimated associations were relatively large in magnitude, consistent with findings from high-income countries, and robust to potential confounding by time-invariant factors. Intensive health sector responses to reduce IPV and improve women's mental health should be explored.
Osteosarcoma in patients over 65 years old
Authors: A. Longhi, C. Errani, C. Ferrari, F. Bertoni, P. Bacchini, M. Mercuri, G. Bacci, P. Picci, S. Ferrari
Journal: Journal of Clinical Oncology (2007)

10037 Background: Few data are available in literature about osteosarcoma in patients older than 65.We reviewed the incidence and outcome of osteosarcoma in elderly over 65 in our casistic. Materials and Methods: Patients with high grade osteosarcoma treated in our Institute from 1961 to 2006 aged &gt;65. End point was overall survival (OS). Results: 43 patients aged more than 65 treated for high grade osteosarcoma at our Institute were found: 22 male and 21 females, median age was 69 (range 65–80), 29 had localized disease and 13 were metastatic, 33 had extremity localization and 10 axial, 29 patients had a primitive osteosarcoma and 13 (30%) had a sarcoma in Paget's disease, 1 pt ha post-RT osteosarcoma. Median interval from symptoms to diagnosis was 4 months (0–73) 32 out of 43 received surgery for primitive tumour: 18 had a resection with endoprosthesis, 13 had amputation, 1 pt had palliative surgery, the others received palliative RT, 14 patients received chemotherapy (anthracycline, cisplatin, ifosfamide).2 major complication related to chemotherapy were observed: one toxic death and one septic shock. Twenty-one patients reached a disease free status after surgery. Median OS for all 43 pts was 19 months (SE 3),mean 35 mos (range 3–229), 3 years OS for the all group was 25%. Three years OS (Kaplan-Meyer) for pts with localized disease was 41,5% vs 0% for metastatic pts, 3 yrs OS for pts who had surgery was 30% compared to 0% for those without surgical treatment.Significant prognostic factors (Breslow statistic) were: localized vs metastatic (P&lt;0,004) and surgery vs no surgery (P&lt;0.00005,) The other variables (sex, type of surgery, chemotherapy) were not statistically significant.In another study on patients aged 40–60 with localized osteosarcoma of the extremity we found an OS at 8 years of 62%. Conclusions: Osteosarcoma in this subgroup of elderly is frequently associated to Paget disease and their OS is worse compared to adult of younger age. We need to improve our strategy of treatment to increase the cure rate of these elderly patients. No significant financial relationships to disclose.
Enhancement of Growth of Human Colon Tumor Cell Lines by Feeder Layers of Murine Fibroblasts&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: M G Brattain, D E Brattain, A M Sarrif, L J McRae, W D Fine, J G Hawkins
Journal: JNCI Journal of the National Cancer Institute (1982)

The effects of feeder layers of C3H/10T 1/2 cells on the growth of human and mouse cell lines were tested. Feeder layers increased colony formation by cultured cancerous cells in semisolid medium over controls grown in semisolid medium without feeder layers. Maximal colony formation was also attained at a faster rate when feeder layers were used. Plating efficiency by cancerous cells obtained directly from xenografts was increased threefold to fivefold in tissue culture when feeder cells were present as confluent monolayers.
Abstract 18012: Insights into the Cardiorenal Syndrome Type II in the Rat
Authors: Annalisa Angelini, Chiara Castellani, Maria G Virzì, Marny Fedrigo, Gaetano Thiene, Marialuisa Valente, Claudio Ronco, Giorgio Vescovo
Journal: Circulation (2013)

Cardiorenal Syndrome Type II (CRSII) is kidney function deterioration in the presence of Chronic Heart Failure (CHF). The mechanisms leading to kidney damage in CHF are however still obscure. We studied the development of kidney injury in a model of right CHF monocrotaline (MCT) treated rats. Methods: 10 Sprague-Dawley rats were treated with MCT for 4 weeks until they developed HF. 11 were taken as control (C). Heart failure was confirmed on transverse heart histologic sections looking at RV hypetrophy /dilatation and BNP plasma levels. Cytokine profile was assessed by Multiplex array on sera. pNGAL, pCreatinine (ELISA), kidney tissue NGAL (RT-PCR) were performed. Kidney cell apoptosis was assessed by TUNEL. Results: MCT rats showed higher BNP values (MCT 4.7±1.2 vs C 1.5±0.5pg/mL p&lt;0.004 ), marked RV Hypetrophy and dilatation (RVMass/RVVolume MCT 1.46±0.31vs C 2.4±0.8 p&lt;0.01). TNFα (MCT 1325.37±559.95vsC84.46±64.50 pg/ml ), IL1(MCT183.71±51.61vsC78.31±26.07), IL4 (MCT 731.67±154.83 vs C 316.62±12.55pg/ml), IL6 (MCT 5314.983±1632.98 vs C1754.01±188.85), IL10 (MCT2613.10±934.04vs C847.70±152.19 pg/ml) were all increased (p&lt;0.05) as well as Creatinine (MCT 0.95±0.4 vs C 0.57±0.4 ug/mL, p&lt;0.05). Both plasma (MCT 0.56±0.28 vs C 0.25±0.16 ug/mL,p&lt;0.02) and kidney tissue NGAL (MCT 70.7±8.7vs C 32.1±9.9 AU, p&lt;0.001) were significantly increased and a higher number of kidney apoptotic cells was found (MCT 184.01±47.6 vs C 16.3±11.6 cells/mm2, p&lt; 0.0001). In C rats apoptosis was found only on tubular or vascular cells, while in MCT also a lot of interstitial cells was found. In MCT rats apoptosis was found in medullar part of kidney with focal aspect. Conclusion: CHF in the rat is accompanied by deterioration of kidney function (CRSII). A rise of creatinine and NGAL, an early biomarker of kidney damage, was detected. Kidney cells apoptosis triggered by circulating pro-inflammatory cytokines represent the final insult to the kidney due to the CHF-induced perturbation of neuro-endocrine and inflammatory milieu.
Monoclonal Antibodies to Human Osteosarcoma-Associated Antigen(s)&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: K Y Tsang, R Q Warren, L Bishop, S Pathak, B Koger, M F LaVia
Journal: JNCI Journal of the National Cancer Institute (1986)

Monoclonal antibodies (MoAbs) against human osteosarcoma cells were obtained by the production and cloning of hybrids resulting from the fusion of mouse myeloma cells P3 X 63Ag8.653 with spleen cells from partially purified, osteosarcoma-associated antigen (OSAA)-immunized BALB/c mice. OSAAs were isolated from the spent culture medium of a human osteosarcoma cell line (TE-85). Five hybrid clones were established and designated as OSA1, OSA2, OSA3, OSA4, and OSA5. OSA1 and OSA2 had similar activity. All 5 MoAbs reacted strongly with most osteosarcoma cell lines and with all osteosarcoma tissues tested but not with 10 tumor cell lines and 2 tumor tissues from other cancers. OSA3, OSA4, and OSA5 cross-reacted with a fibrosarcoma cell line, a colon cell line, and fibrosarcoma, respectively, as well as with a melanoma cell line. None of the MoAbs were reactive with activated normal human peripheral blood mononuclear cells (PBMC). Immunoprecipitation of membrane protein isolated from LM cells and TE-85 cells with the MoAbs OSA1 and OSA2 conjugated with Staphylococcus aureus yielded a molecule with molecular weight of approximately 92,000. No detectable membrane protein was precipitated when 125I-labeled membrane protein from pooled activated human PBMC and tumor cells of other histologic types were used in the immunoprecipitation.
A Multi-Institutional Surveillance of Clinicopathological Features and Molecular Epidemiology of Egfr Mutations in Lung Cancer Patients Living with Human Immunodeficiency Virus Infection in Japan
Authors: Y. Okuma, J. Tanuma, H. Otera, Y. Kojima, M. Yotsumoto, T. Uehira, Y. Takeda, H. Nagai, A. Ajisawa, Y. Setoguchi, S. Okada
Journal: Annals of Oncology (2014)
Influence of Chemotherapeutic Agents on Chorionic Gonadotropin-Alpha Subunit Secretion in a Human Lung Cancer Cell Line (ChaGo): Discordance of Cytotoxic and Secretory Effects&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Lawrence E. Broder, M.D., Bruce D. Weintraub, M.D., Saul W. Rosen, M.D.
Journal: JNCI Journal of the National Cancer Institute (1978)

Cells from cultures of ChaGo, a cell line of a human lung cancer that ectopically produces chorionic gonadotropin (hCG) and its alpha subunit (hCG-α) were exposed to five different cancer chemotherapeutic agents in vitro in separate experiments (one drug/expt). The control doubling time averaged 4 days, with molar biphasic secretory rates of hCG-α ranging from a high of 58.1 to a low of 10.5 pmoles/106 cells/24 hours. Drug concentrations were chosen to induce a 30–60% inhibition of cell replication over a period of 8–10 days. Neither methotrexate nor vincristine demonstrated major effects on extracellular hCG-α production, but each agent moderately depressed cell number and each produced major inhibition of intracellular protein synthesis. Procarbazine inhibited marker production only in slight excess of inhibition of cell growth and cell protein. Actinomycin D and mechlorethamine, however, had profound effects on inhibition of hCG-α production in excess of cell growth. Our results indicated that cancer chemotherapeutic agents have specific and differing effects on cell growth and cell protein on the one hand and marker production on the other. These data suggested a mechanism for certain cases of discordance between hormone production and clinical status.
Differences in adherence to common inhaled medications in COPD
Authors: Kirsten Koehorst-ter Huurne, Kris Movig, Paul vanderValk, Job van der Palen, Marjolein Brusse-Keizer
Journal: European Respiratory Journal (2013)

Objective: To study differences in adherence to common inhaled medication in COPD.

Methods: Therapy adherence of 795 patients was recorded from pharmacy records over 3 years. It was expressed as percentage and deemed good at 75–125%, sub-optimal 50-75%, and poor  125%. Some patients used more than one medication, so we present 1377 medication periods.

Results: The percentages of good adherence ranged from 43.2 (beclometason) - 75.8% (tiotropium); suboptimal from 2.3 (budesonide) - 23.3% (fluticasone);  125 from 5.1 (salmeterol) - 38.6% (budesonide). (table 1)

View this table:

Table 1: Number (%) of patients in the adherence subgroups





Conclusion: Tiotropium showed the highest adherence, followed by ciclesonide, both dosed once daily. Adherence with solely salmeterol and fluticason is higher than the combined preparation. For formoterol/budesonide adherence is better than budesonide alone. The idea of improving adherence by using combined preparations cannot be confirmed in this study.